B
Benitec Biopharma Inc. (BNTC)
10.27
0.00 (0.00%)
Get all premium features to the best stock analysis tool
10.27
0.00 (0.00%)
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
| Name | Position |
|---|---|
| Dr. Claudia Kloth Ph.D. | Senior Vice President of Manufacturing |
| Dr. Michael Graham | Head of Discovery & Founding Scientist |
| Ms. Sophie Mukadam | Chief Operating Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-20 | 10-K/A | d226768d10ka.htm |
| 2026-01-30 | S-3 | d10746ds3.htm |
| 2025-12-02 | 8-K | bntc-20251201.htm |
| 2025-11-14 | 8-K | d811784d8k.htm |
| 2025-11-12 | DEFA14A | d75431ddefa14a.htm |
| 2025-11-03 | 8-K | bntc-20251102.htm |
| 2025-10-14 | DEF 14A | d32674ddef14a.htm |
| 2025-09-26 | CORRESP | filename1.htm |
| 2025-09-22 | 8-K | bntc-20250922.htm |
| 2025-09-12 | 8-K | bntc-20250910.htm |